title: [Experimental and clinical studies of drug regulation of the anti-lysozyme activity of microorganisms causing opportunistic infections].
abstract: Experimental materials on choosing antibiotics for etiotropic therapy of opportunistic infections with an account of the regulating effect of the drugs on the ++anti-lysozyme activity of pathogens (the factor of intracellular parasitism) are presented. The in vitro data were applied to the clinical trials in 30 patients with chronic and acute pyelonephritis of the Proteus etiology and to 25 patients with chronic inflammatory diseases of Staphylococcus etiology. It was shown that the use of the antibiotics which lowered the ++anti-lysozyme activity of microorganisms promoted a more rapid disappearance of the disease clinical signs, increased 2- to 3-fold the terms of the remission and resulted in an increase in the number of the persons with complete remission (54.5 to 63.6 per cent) as compared to the use of the drugs which stimulated the pathogen property or were indifferent to it.
authors.forename: O V
authors.initials: OV
authors.lastname: Bukharin
authors.forename: B Ia
authors.initials: BIa
authors.lastname: Usviatsov
authors.forename: L A
authors.initials: LA
authors.lastname: Pervushina
authors.forename: O L
authors.initials: OL
authors.lastname: Zaikina
authors.forename: S V
authors.initials: SV
authors.lastname: Rishchuk
authors.forename: E V
authors.initials: EV
authors.lastname: Surikova
authors.forename: N V
authors.initials: NV
authors.lastname: Sheenkov
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000502:physiology; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D004793:Enzyme Reactivators; D004794:Enzyme Repression / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D009113:Muramidase / Q000096:biosynthesis / Q000276:immunology*; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D004793:Enzyme Reactivators; D009113:Muramidase